Polycystic Ovarian Syndrome Market Research Report – Forecast to 2032

Polycystic Ovarian Syndrome Market Research Report Information By Diagnosis (Pelvic Examination, Ultrasound, Blood Tests), Treatment ([Oral Contraceptives, Antiandrogens, Insulin Sensitizing Agent, Antidepressant, Anti-Obesity, Surgery {Ovarian Wedge Resection and Laparoscopic Ovarian Drilling}]), End-User (Hospitals & Clinics, Ambulatory Surgical Centers), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2032

ID: MRFR/Pharma/4834-HCR | 100 Pages | Author: Rahul Gotadki | February 2024         

Polycystic Ovarian Syndrome Market Speak to Analyst Request a Free Sample

Global Polycystic Ovarian Syndrome  Market Overview


Global Polycystic ovarian syndrome Market Size was valued at USD 2.8 billion in 2022 and is projected to grow from USD 2.93 Billion in 2023 to USD 4.26 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.8% during the forecast period (2023 - 2032). The rising frequency of diabetes, the use of less invasive surgery, and the rise in female hormonal diseases are the key market drivers enhancing the market growth.
Polycystic Ovarian Syndrome Market Overview
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review


Polycystic ovarian syndrome Market Trends



  • A Rise in the frequency of and knowledge of polycystic ovarian syndrome among patients will boost market growth.


An increase in polycystic ovarian syndrome prevalence, patient population awareness, and the use of combination therapy drives the growth of the polycystic ovarian syndrome treatment market. Additionally, the market growth is influenced by the ease of access to polycystic ovarian syndrome therapies, increased demand for polycystic ovarian syndrome drugs, and technological developments for cancer screening. However, the absence of authorized treatments and the unclear pathophysiology and etiology of the polycystic ovarian syndrome are expected to restrain market expansion. Additionally, throughout the anticipated time, the emerging countries' untapped potential offers profitable chances for the expansion of the polycystic ovarian syndrome treatment market. However, the absence of specialized therapy for polycystic ovarian syndrome disease is anticipated to impede the expansion of the industry. The need for polycystic ovarian syndrome treatment drugs is anticipated to increase as polycystic ovarian syndrome becomes more common. For instance, according to the Centers for Disease Control and Prevention, the polycystic ovarian syndrome affects 6 to 12% (or as many as 5 million) of American women of reproductive age. It is one of the most prevalent reasons for female infertility. Due to the rising prevalence of co-morbid illnesses, including diabetes and obesity, more people have PCOS. Thus, this factor is driving the market CAGR.


Over the projected period, it is also anticipated that increasing spending on R&D activities and the release of innovative medications would spur market expansion for pharmaceuticals treating polycystic ovary syndrome. However, a shortage of FDA-approved medications, a lack of polycystic ovarian syndrome awareness in developing nations, and rising adverse effects from generic medications might restrain market expansion throughout the projection period.


The market is anticipated to be driven by several government and private sector efforts to raise awareness of the illness. For example, in June 2020, research funded by the National Institutes of Health's Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Diabetes and Digestive and Kidney Diseases, titled "Different subtypes of polycystic ovarian syndrome with new genetic associations: An unsupervised, phenotypic clustering analysis," revealed that polycystic ovary syndrome might have at least two distinct subtypes. Thus, it is anticipated that this aspect will accelerate polycystic ovarian syndrome  market revenue globally.


Polycystic Ovarian Syndrome Market Segment Insights


Polycystic Ovarian Syndrome Diagnosis Insights


Based on Diagnosis, the global polycystic ovarian syndrome market segmentation includes a pelvic examination, ultrasound, and blood tests. The ultrasound segment dominated the market growth in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030.  ovaries condition and the thickness of your uterus' lining may be examined with an ultrasound. Your vagina receives a transducer, which resembles a wand. Sound waves released by the transducer are converted into visuals on a computer screen.


Figure1: Polycystic Ovarian Syndrome Market, by Diagnosis, 2021 & 2030 (USD Million)\
Polycystic Ovarian Syndrome Market, by Diagnosis, 2021 & 2030
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review


Polycystic Ovarian Syndrome Treatment Insights


The global polycystic ovarian syndrome market segmentation, based on Treatment, includes Oral Contraceptives, Antiandrogens, Insulin Sensitizing Agent, Antidepressant, Anti-Obesity, Surgery (Ovarian Wedge Resection and Laparoscopic Ovarian Drilling). The surgery segment held the majority share in 2022 in the global Polycystic ovarian syndrome market data One of the most frequent operations surgeons perform in life-threatening situations is laparoscopic ovarian drilling (LOD). Since polycystic ovarian syndrome is a key contributing factor to women's reproductive issues and treatment response deteriorates over time, abdominal surgery using a thin microscope is highly preferred globally.


According to research published in the Cochrane Library in July 2020 under the title "Laparoscopic ovarian drilling for ovulation induction in women with anovulatory polycystic ovary syndrome," if the chance of a live birth following medical ovulation induction alone is 42%, the chance of a live birth following LOD is between 28% and 40%. According to the study, laparoscopic drilling is highly likely to succeed in women, which is why it is the procedure of choice. Patients are drawn to this surgical technique due to its simplicity of illness treatment and cost-effectiveness. As a result, it is predicted to have a sizable share throughout the projection period.


Polycystic ovarian syndrome End-user Insights


Based on End-user, the global polycystic ovarian syndrome market segmentation includes Hospitals & Clinics and Ambulatory Surgical Centers. The Hospitals & Clinics segment dominated the Polycystic ovarian syndrome  market revenue in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. In 2021, Ambulatory Surgical Centers ranked second in terms of market size. Due to the present rise in polycystic ovarian syndrome incidence and the rising number of procedures performed in hospital settings, the hospital segment is predicted to develop at the quickest rate. Polycystic ovarian syndrome is often diagnosed and treated in hospitals. Since no one test can be used to precisely identify polycystic ovarian syndrome (PCOS), clinicians must determine this for patients with the polycystic ovarian syndrome.


Polycystic Ovarian Syndrome Regional Insights


By Region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. In North America, the Polycystic ovarian syndrome market accounted for USD 1.3 billion in 2021 and is expected to exhibit a significant CAGR growth during the study period. One of the major reasons driving the market growth in North America is the rise in polycystic ovarian syndrome cases due to rising rates of obesity and overweight. In addition, more people are becoming aware of the advantages of routine checkups, increasing the number of new cases detected here each year. The United States dominates the North American Polycystic ovarian syndrome market with the highest revenue share. This market is expanding mostly due to this nation's huge number of polycystic ovarian syndrome sufferers. Furthermore, the U.S.'s ability to attract large market participants like Merck, Abbott, and BMS would substantially impact the nation's ability to generate income.


Further, the major countries studied in the market report are The U.S., Canada, Germany, France, the U.K., Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.


Figure 3: POLYCYSTIC OVARIAN SYNDROME  MARKET SHARE BY REGION 2021 (%)
POLYCYSTIC OVARIAN SYNDROME  MARKET SHARE BY REGION 2021
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review


Asia Pacific Polycystic ovarian syndrome Market together make up most of the population in the Asia Pacific region. As a result, the Region's polycystic ovarian syndrome treatment market has tremendous development potential due to the presence of a sizable target patient pool. The governments of these nations are concentrating on reducing the rising prevalence of polycystic ovarian syndrome by implementing initiatives that promote the Diagnosis, Treatment, and necessary lifestyle change of this syndrome. These initiatives raise public awareness of the polycystic ovarian syndrome and its hazards, including the emergence of insulin resistance, obesity, and occasionally infertility. Shortly, the Asia Pacific market is anticipated to be driven by these reasons. Further, the China Polycystic ovarian syndrome  market held the largest market share, and the India Polycystic ovarian syndrome  market was the fastest growing market in the region.


Due to improvements in healthcare infrastructure, an increase in the number of target populations, a growing R&D sector, an increase in healthcare reforms, and technical developments in the healthcare field, Europe Polycystic ovarian syndrome Market will have the third-highest growth during the projected period of 2021. Moreover, U.K. Polycystic ovarian syndrome Market held the largest market share, and the Germany Polycystic ovarian syndrome  Market was the fastest-growing market in the Region.


Polycystic ovarian syndrome  Key Market Players & Competitive Insights


Major market players are investing a lot of money in R&D to expand their product portfolios, which will spur further market growth for cervical fusion. With significant industry changes, including new product releases, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations, market developments are also undertaking various strategic activities to expand their global presence. To grow and remain in a market that is becoming more and more competitive, polycystic ovarian syndrome industry competitors must provide affordable products.


Manufacturing locally to cut operational costs is one of the main business tactics used by the Polycystic ovarian syndrome industry to serve customers and increase the market sector. The Polycystic ovarian syndrome industry has recently given medicine some of the most important advantages. The Polycystic ovarian syndrome market major player such as Bayer AG, AstraZeneca plc, Abbott, Biocinese, Catalysis, S.L., Crinetics Pharmaceuticals, Inc., Sanofi, Eugonia, EffRx, Inc., Ferring Pharmaceuticals, Inc., Merck KGaA, Bristol-Myer Squibb Company, Neurocrine Biosciences, Inc., Reliance Life Sciences Pvt. Ltd. Pfizer, Inc., Novartis AG, and Shire Plc., and others are working to expand the market demand by investing in research and development activities.


Founded in 2013, the American biopharmaceutical business AbbVie is publicly listed. It began as an Abbott Laboratories spin-off. Abbvie was conducting a clinical study in women with polycystic ovarian syndrome to determine the safety and effectiveness of the drug Elagolix January 2020. Elagolix's safety and effectiveness in treating women with Polycystic ovarian syndrome are now being examined in a Phase 2 multicenter, double-blind, randomized, placebo-controlled study being carried out by the company (PCOS).


One of the biggest pharmaceutical firms in the world is Bayer AG, a global German pharmaceutical and biotechnology corporation. • In January 2020, Evotec S.E. and Bayer AG announced the start of a new, multi-target, five-year cooperation with Celmatix Inc. to develop several clinical candidates for the management of polycystic ovarian syndrome, which is anticipated to dominate the market for the whole forecast period. In January 2020, Abbvie will begin a clinical trial employing the drug Elagolix, which is being tested for both safety and effectiveness in treating Polycystic ovarian syndrome in female patients. Elagolix's safety and effectiveness in treating women with polycystic ovarian syndrome are being examined in the Phase 2 multicenter, double-blind, randomized, placebo-controlled study that the company is now doing.


Key Companies in the polycystic ovarian syndrome market include



  • Bayer AG

  • AstraZeneca plc

  • Abbott, Biocinese

  • Catalysis, S.L.

  • Crinetics Pharmaceuticals, Inc.

  • Sanofi, Eugonia, EffRxnInc.

  • Ferring Pharmaceuticals Inc.

  • Merck KGaA

  • Bristol-Myer Squibb Company

  • Neurocrine Biosciences Inc.

  • Reliance Life Sciences Pvt. Ltd.

  • Pfizer, Inc.

  • Novartis AG

  • Shire Plc.


Polycystic Ovarian Syndrome Industry Developments



  • December 2021 A global provider of women's healthcare, Organon, purchased Forendo Pharma, a firm specializing in clinical-stage medication development for women's health. A polycystic ovarian syndrome-focused preclinical program is part of Forendo's pipeline (PCOS).

  • January 2020 A new five-year multi-target partnership between Evotec S.E. and Bayer AG and Celmatix Inc. is underway to develop several clinical candidates for the management of polycystic ovarian syndrome, which is anticipated to dominate the market over the forecast period.

  • January 2022 The ovarian biology-focused biotechnology business Celmatix Inc. announced the achievement of a third milestone in its five-year, multi-target partnership with Evotec. The achievement of the milestone of moving a Polycystic Ovarian Syndrome medication development built around a brand-new therapeutic target discovered by Celmatix towards hit identification was brought about by Evotec and Bayer AG.


Polycystic Ovarian Syndrome Market Segmentation


Polycystic Ovarian Syndrome Diagnosis Outlook



  • Pelvic examination

  • Transvaginal ultrasound

  • Blood tests

  • Hormone levels

  • Glucose tolerance

  • Cholesterol and triglyceride levels


Polycystic Ovarian Syndrome Treatment Outlook



  • Oral Contraceptives

  • Antiandrogens

  • Insulin Sensitizing Agent

  • Antidepressant

  • Anti-Obesity

  • Surgery

  • Ovarian Wedge Resection

  • Laparoscopic Ovarian Drilling


Polycystic Ovarian Syndrome End-User Outlook



  • Hospitals & Clinics

  • Ambulatory Surgical Centers

  • Diagnostic Centers

  • Gynecology Centers

  • Feminist Health Centers


Polycystic ovarian syndrome Regional Outlook




  • North America



    • US

    • Canada




  • Europe



    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Rest of Europe




  • Asia-Pacific



    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Australia

    • Rest of Asia-Pacific




  • Rest of the World




    • Middle East




    • Africa




    • Latin America





Report Scope:

Report Attribute/Metric Details
Market Size 2021 USD 2.8 billion
Market Size 2022 USD 2.93 billion
Market Size 2032 USD 4.26 billion
Compound Annual Growth Rate (CAGR) 4.80% (2023-2032)
Base Year 2021
Market Forecast Period 2022-2032
Historical Data 2018 & 2020
Market Forecast Units Value (USD Billion)
Report Coverage Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
Segments Covered Diagnosis, Treatment, End-User and Region
Geographies Covered North America, Europe, Asia Pacific, and the Rest of the World
Countries Covered The U.S, Canada, Germany, France, the U.K., Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
Key Companies Profiled Bayer AG, AstraZeneca plc, Abbott, Biocinese, Catalysis, S.L., Crinetics Pharmaceuticals, Inc., Sanofi, Eugonia, EffRx, Inc., Ferring Pharmaceuticals, Inc., Merck KGaA, Bristol-Myer Squibb Company, Neurocrine Biosciences, Inc., Reliance Life Sciences Pvt. Ltd. Pfizer, Inc., Novartis AG, and Shire Plc.
Key Market Opportunities Increasing healthcare expenditure Increasing technological advancements
Key Market Dynamics Increasing hormonal disorders in women  Adoption of minimally invasive surgeries  Rising prevalence of diabetes




Frequently Asked Questions (FAQ) :

The global Polycystic ovarian syndrome market size was valued at USD 2.8 Billion in 2022.

The global polycystic ovarian syndrome market is projected to grow at a CAGR of 4.80% during the forecast period 2023-2032.

North America had the largest share in the global polycystic ovarian syndrome market.

The key players in the market are Bayer AG, AstraZeneca plc, Abbott, Biocinese, Catalysis, S.L., Crinetics Pharmaceuticals, Inc., Sanofi, Eugonia, EffRx, Inc., Ferring Pharmaceuticals, Inc., Merck KGaA, Bristol-Myer Squibb Company, Neurocrine Biosciences, Inc., Reliance Life Sciences Pvt. Ltd. Pfizer, Inc., Novartis AG, and Shire Plc.

The anterior Polycystic ovarian syndrome category dominated the market in 2021.

Minimally invasive spine surgery had the largest share in the global polycystic ovarian syndrome market.

Key Questions Answered

  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Request Free Sample

Why Choose Market Research Future?

  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.
Speak to Analyst
Leading companies partner with us for data-driven Insights.
Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response
Invalid